Optimind Pharma Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

David Goodman

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	geen gegevens

Recente managementupdates

Recent updates

CEO

David Goodman

less than a year

Tenure

Mr. David Goodman serves as an Independent Director of Predictmedix AI Inc. since December 14, 2023. He was an Independent Director of Optimind Pharma Corp. since October 7, 2022 until January 2024 & serve...

Optimind Pharma Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Less than half of directors are independent

Less than half of directors are independent

Optimind Pharma Corp. Announces Executive Changes

Optimind Pharma Corp., Annual General Meeting, Jul 20, 2023

Recent updates

Second quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.002 loss in 2Q 2024)

First quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.004 loss in 1Q 2024)

Optimind Pharma Corp. announced that it expects to receive CAD 0.5 million in funding

Optimind Pharma Corp. announced that it expects to receive CAD 0.5 million in funding

Full year 2024 earnings released: CA$0.014 loss per share (vs CA$0.038 loss in FY 2023)

Less than half of directors are independent

Less than half of directors are independent

Third quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.01 loss in 3Q 2023)

Optimind Pharma Corp. Announces Executive Changes

Second quarter 2024 earnings released: CA$0.002 loss per share (vs CA$0.01 loss in 2Q 2023)

First quarter 2024 earnings released

Optimind Pharma Corp., Annual General Meeting, Jul 20, 2023

Optimind Pharma Corp. (CNSX:OMND) acquired MindSetting Inc. from Beatrice Society Inc. for CAD 1.6 million.

CEO

Tenure